| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2169875 | Current Opinion in Cell Biology | 2013 | 8 Pages |
Abstract
Cell cycle progression is controlled by sequential activation of cyclin-dependent kinases (CDKs), which are often deregulated in cancer. Consequently numerous pharmacological inhibitors of CDKs have been developed with the aim of treating cancers. The article briefly reviews CDK inhibitors and their use to treat cancers, with specific focus on the use of biomarkers and drugs combination to improve their therapeutic efficacy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Céline Bruyère, Laurent Meijer,